Any screening approach, including with cell-free DNA, will have an inferior detection rate compared with 100% diagnostic testing with chromosomal microarrays. Cell-free DNA-based screening, however, should not be seen as a threat to informed choice or maximising the benefits of diagnostic testing. Screening methods have become so much better that more women are now comfortable relying on such screening and do not need the certainty of a diagnostic test. This has not lead to a decline in detection of fetal chromosome abnormalities-in fact, we are now seeing historically high yields from prenatal screening.
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There are both economic and ethical consequences of offering universal diagnostic testing and abandoning the presumption of a normal infant in otherwise uncomplicated pregnancies.
However, for some women, comprehensive information and diagnostic accuracy are important.
Offering these women all options, with a careful and comprehensive explanation of the risks and benefits of each, results in outcomes that are best aligned with woman's preferences while at the same time requiring fewer diagnostic tests and lowering costs. It is one of the primary challenges of the modern era of prenatal testing to ensure that women receive sufficient information on which to make informed decisions.
| INTRODUCTION
In the accompanying commentary 1 , 2 trends in prenatal testing are framed as competing-the reduction in diagnostic testing because of cell-free DNA-based (cfDNA) screening and the increased diagnostic capacity of chromosomal microarrays (CMA). They provide a simplified cost-benefit analysis of universal diagnostic testing with CMA combined with the option of pregnancy termination for pathogenic findings and conclude that this may be more cost-effective than screening approaches.
| HAVE WOMEN REALLY "PAID A PRICE" FOR EMBRACING CFDNA?
Evans and colleagues refer to the recent changes in practice as a "shift from diagnostics to screening." While "shift" may describe the numerical trends in prenatal testing, our fundamental screening paradigm has not changed. Rather, screening has improved enough that for many women, this is adequate and is preferable to diagnostic testing.
Diagnostic tests are still positioned as follow-up confirmation after screening, including screening with maternal age alone, and universal diagnostic testing is not a recommended approach that is being abandoned in favour of screening. Any screening approach, including with cfDNA, will have inferior detection compared with 100% diagnostic testing with CMA.
It is important to recognize that the decrease in diagnostic testing is a trend that began before the introduction of cfDNA screening.
Population-based data from the Australian state of Victoria, as well as from the Kaiser Permanente health system in Northern California, demonstrate that the reduction in diagnostic testing is a long-standing trend that predated cfDNA. In Victoria, diagnostic testing rates peaked at 8.9% of all births in the 1990s when maternal age and second trimester serum screening were the most common indications for testing, and began to decline following the introduction of combined first trimester screening (CFTS) in 2000 ( Figure 1A ). 2 In the Kaiser system, similarly, decreases in rates of diagnostic testing were seen in the decade before the introduction of cfDNA screening. 3 So, has the overall decline in testing led to a reduction in the pre- MoM, or fetal abnormality on first or second trimester ultrasound. 5 Therefore, in our population, women have reaped the benefits of advances in both screening (CFTS +/or cfDNA + ultrasound) and diagnostic testing (CMA), although the benefits of cfDNA may not be equitably distributed across all socioeconomic groups. 6 These complementary-not competing-advances have resulted in record yields from diagnostic testing: In the most recent published data, only 5 diagnostic tests were needed to detect each major chromosome abnormality. 4 In fact, it could be argued that the "price" of performing fewer diagnostic tests has actually been borne by the medical profession via its downstream effect on training, skills maintenance, and clinical practice volume. short-term and long-term harm-both financial and psychological-is a major consideration when considering implementation of universal diagnostic testing. 8 Couples who receive a diagnosis of a variant of unknown or uncertain significance (VUS) may then experience a difficult and stressful pregnancy, whether or not they ultimately deliver a healthy infant. Furthermore, this anxiety may continue for years as the parents watch their child for the emergence of a suspected phenotype. 9 It could certainly be argued that this is a hidden price to be paid for offering universal diagnostic testing and abandoning the presumption of a normal infant in otherwise uncomplicated pregnancies.
What's already known about this topic?
• Prenatal diagnostic testing has been declining for over 20 years, and this trend has been exacerbated by the recent introduction of cell-free DNA-based (cfDNA) screening.
• At the same time, the diagnostic capacity of prenatal testing has increased with the development of chromosomal microarrays.
• The risk of a pathogenic copy number variant in the general population is considered sufficiently high by some opinion leaders to consider offering prenatal diagnosis to all women.
What does this study add?
• cfDNA screening should be not seen as a threat to informed choice and the diagnostic yield of prenatal testing.
• The detection of major chromosome abnormalities has increased, rather than decreased, since the introduction of cfDNA screening and chromosomal microarrays.
• Cost-utility analyses that include patient preferences show higher utility for a traditional screening approach than for universal diagnostic testing.
• Ensuring that all women receive adequate information about their options is one of the primary challenges in prenatal testing.
| COST-UTILITY AND THE IMPORTANCE OF PATIENT PREFERENCES
The Furthermore, when women do decide to have an invasive procedure, they may not wish to have maximum genomic information about penetrance and to forgo information on VUS and susceptibility genes.
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In another recent study, a cost utility analysis was performed to assess outcomes of 6 testing strategies, including diagnostic testing with CMA, cfDNA screening, or traditional serum and nuchal translucency-based screening, alone, in combination, or in sequence. 12 Quality-adjusted life years were measured in a cohort of women using time trade-off utilities, and outcomes considered included birth of a child with a chromosome abnormality, as well as miscarriage, detection of a VUS, and termination of an abnormal fetus, among others. The probabilities for each of these outcomes were obtained from the literature. Although diagnostic testing resulted in the most abnormalities detected, interestingly, cfDNA or traditional screening with low-risk results had a higher utility than diagnostic testing with normal results.
Furthermore, traditional screening was the most cost-effective until maternal age 40, when cfDNA was the optimal test and most costeffective. Again, this model, which was far more complex and considered many more outcomes than that described by Evans et al, had
quite different (and somewhat surprising) results when women's preferences were measured and considered.
Obviously, such models are complex, and individuals will often indicate a planned, hypothetical behaviour that is different than what they actual choose when faced with real-life circumstances. This is often the case with prenatal testing, in which women may state a preference for obtaining the most information, but when actually pregnant and needing to make a decision, they are willing to rely on a screening test and accept a modestly lower detection rate.
| CONCLUSION
cfDNA screening should not be seen as a threat to informed choice.
Rather, we must acknowledge that as screening methods have become so much better-more specific and sensitive-women are comfortable relying on such screening to put them in a low-risk category, and many do not feel they need the certainty of a diagnostic test. These changes have not led to a decline in detection of fetal chromosome abnormalities-in fact, we are now seeing historically high yields from prenatal testing.
That being said, for some women, comprehensive information and certainty are important. Offering such women all options, with a careful and comprehensive explanation of the risks and benefits of each, results in outcomes that are best aligned with women's preferences while at the same time requiring fewer diagnostic tests and therefore lowering costs. This is one of the primary challenges of the modern era of prenatal testing-to ensure that women understand their choices and have adequate and accurate information on which to make informed decisions.
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